Pembrolizumab
Merck
['nsclc', 'sclc', 'lcsm,(-blcsm)', 'pearls', 'pearl', 'keynote,91', 'pembro']
pearls/keynote-091: adjuvant pembrolizumab in nsclc patients after complete resection by . relatively higher efficacy has been reported with pd-l1 0-49% in contrast to the advanced settings. just a fluctuation of subgroups? or a sign of biology? #lcsm #esmo22 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC